FDA Approves Mogamulizumab-kpkc Mycosis Fungoides or Sézary Syndrome
Aug 08
2018
The Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo, Kyowa Kirin, Inc.) for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
